Fixed Dose Flavonoid Isoquercetin on Thrombo-Inflammatory Biomarkers in Subjects With Stable Sickle Cell Disease

PHASE2CompletedINTERVENTIONAL
Enrollment

46

Participants

Timeline

Start Date

November 2, 2020

Primary Completion Date

June 13, 2022

Study Completion Date

July 7, 2022

Conditions
Sickle Cell Disease
Interventions
DRUG

Isoquercetin

"Isoquercetin (quercetin-3-O-beta-D-glucoside, also referred to as isoquercitrin) is a naturally occurring monoglucoside of the most studied and widely consumed bioflavonoid, quercetin.~Isoquercetin given at 1000 mg, once daily by mouth for 28 days."

DRUG

Placebo

"Silicified microcrystalline cellulose NF, Ascorbic acid, Nicotinic acid, Mg stearate, Silica and Colloidal Anhydrous Ph. Eur./Colloidal Silicon dioxide USP/NF.~Placebo give at 1000 mg, once daily by mouth for 28 days."

Trial Locations (1)

20892

National Institutes of Health Clinical Center, Bethesda

All Listed Sponsors
collaborator

Quercis Pharma AG

INDUSTRY

lead

National Heart, Lung, and Blood Institute (NHLBI)

NIH

NCT04514510 - Fixed Dose Flavonoid Isoquercetin on Thrombo-Inflammatory Biomarkers in Subjects With Stable Sickle Cell Disease | Biotech Hunter | Biotech Hunter